HasanSJamdarSFAlalowiMAl AgeelAlBeaijiSM.Dengue virus: a global human threat: review of literature. J Int Soc Prev Community Dent. 2016;6(1):1-6. doi:10.4103/2231-0762.175416.
Epidemiological Alert: Increase in Dengue Cases in Central America and the Caribbean. Washington, DC: Pan American Health Organization; Geneva: World Organization of Health; 2023.
KatzelnickLCGreshLHalloranME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science (New York, NY). 2017;358(6365):929-932. doi:10.1126/science.aan6836.
6.
TayalAKabraSKLodhaR.Management of dengue: an updated review. Indian J Pediatr. 2023;90(2):168-177. doi:10.1007/s12098-022-04394-8.
CochetACalbaCJourdainF, et al. Autochthonous dengue in mainland France, 2022: geographical extension and incidence increase. Euro Surveill. 2022;27(44):2200818. doi:10.2807/1560-7917.Es.2022.27.44.2200818.
HaiderNAsaduzzamanMHasanMN, et al. Bangladesh’s 2023 Dengue outbreak—age/gender-related disparity in morbidity and mortality and geographic variability of epidemic burdens. Int J Infect Dis. 2023;136:1-4. doi:10.1016/j.ijid.2023.08.026.
12.
ThomasSJ.Is new dengue vaccine efficacy data a relief or cause for concern?NPJ Vaccines. 2023;8(1):55. doi:10.1038/s41541-023-00658-2.
13.
Paz-BaileyGAdamsLWongJM, et al. Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021. MMWR Recomm Rep. 2021;70(6):1-16. doi:10.15585/mmwr.rr7006a1.
CapedingMRTranNHHadinegoroSR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358-1365. doi:10.1016/s0140-6736(14)61060-6.
16.
VillarLÁRivera-MedinaDMArredondo-GarcíaJL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32(10):1102-1109. doi:10.1097/INF.0b013e31829b8022.
17.
BiswalSReynalesHSaez-LlorensX, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381(21):2009-2019. doi:10.1056/NEJMoa1903869.
18.
RiveraLBiswalSSáez-LlorensX, et al. Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2022;75(1):107-117. doi:10.1093/cid/ciab864.